COMPASS THERAPEUTICS, INC. Comprehensive Income
COMPASS THERAPEUTICS, INC. (CMPX) reported Comprehensive Income of -$25.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$25.25M.
- COMPASS THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$18.76M.
- COMPASS THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$15.71M.
- COMPASS THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$14.19M.
- COMPASS THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$66.42M.
- COMPASS THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$49.20M.
- COMPASS THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$42.16M.
- COMPASS THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$39.53M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$25.25M 10-Q · filed 2026-08-06 | -$44.00M 10-Q · filed 2026-08-06 | -$59.71M derived: sum of 3 quarters · filed 2026-08-06 | -$73.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$18.76M 10-Q · filed 2026-05-05 | -$34.47M derived: sum of 2 quarters · filed 2026-05-05 | -$48.66M derived: sum of 3 quarters · filed 2026-05-05 | -$68.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$15.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$29.90M derived: sum of 2 quarters · filed 2026-03-05 | -$49.77M derived: sum of 3 quarters · filed 2026-08-06 | -$66.42M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$14.19M 10-Q · filed 2025-11-05 | -$34.06M derived: sum of 2 quarters · filed 2026-08-06 | -$50.71M 10-Q · filed 2025-11-05 | -$66.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$19.86M 10-Q · filed 2026-08-06 | -$36.52M 10-Q · filed 2026-08-06 | -$51.83M derived: sum of 3 quarters · filed 2026-08-06 | -$61.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$16.65M 10-Q · filed 2026-05-05 | -$31.96M derived: sum of 2 quarters · filed 2026-05-05 | -$41.87M derived: sum of 3 quarters · filed 2026-05-05 | -$54.94M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$15.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$25.21M derived: sum of 2 quarters · filed 2026-03-05 | -$38.29M derived: sum of 3 quarters · filed 2026-03-05 | -$49.20M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$9.90M 10-Q · filed 2025-11-05 | -$22.98M derived: sum of 2 quarters · filed 2025-11-05 | -$33.89M 10-Q · filed 2025-11-05 | -$46.84M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$13.08M 10-Q · filed 2025-08-11 | -$23.99M 10-Q · filed 2025-08-11 | -$36.94M derived: sum of 3 quarters · filed 2025-08-11 | -$46.83M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$10.91M 10-Q · filed 2025-05-08 | -$23.86M derived: sum of 2 quarters · filed 2025-05-08 | -$33.75M derived: sum of 3 quarters · filed 2025-05-08 | -$45.39M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$12.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$22.84M derived: sum of 2 quarters · filed 2025-02-27 | -$34.47M derived: sum of 3 quarters · filed 2025-02-27 | -$42.16M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$9.89M 10-Q · filed 2024-11-12 | -$21.53M derived: sum of 2 quarters · filed 2024-11-12 | -$29.21M 10-Q · filed 2024-11-12 | -$40.46M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$11.64M 10-Q · filed 2024-08-12 | -$19.32M 10-Q · filed 2024-08-12 | -$30.57M derived: sum of 3 quarters · filed 2024-08-12 | -$42.68M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$7.68M 10-Q · filed 2024-05-13 | -$18.94M derived: sum of 2 quarters · filed 2024-05-13 | -$31.04M derived: sum of 3 quarters · filed 2024-05-13 | -$40.05M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$11.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$23.36M derived: sum of 2 quarters · filed 2024-03-21 | -$32.37M derived: sum of 3 quarters · filed 2024-03-21 | -$39.53M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$12.10M 10-Q · filed 2023-11-09 | -$21.11M derived: sum of 2 quarters · filed 2023-11-09 | -$28.27M 10-Q · filed 2023-11-09 | -$41.25M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$9.01M 10-Q · filed 2023-08-03 | -$16.17M 10-Q · filed 2023-08-03 | -$29.15M derived: sum of 3 quarters · filed 2023-08-03 | -$35.12M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$7.16M 10-Q · filed 2023-05-04 | -$20.14M derived: sum of 2 quarters · filed 2023-05-04 | -$26.12M derived: sum of 3 quarters · filed 2023-05-04 | -$81.92M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$12.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$18.96M derived: sum of 2 quarters · filed 2023-03-15 | -$74.76M derived: sum of 3 quarters · filed 2023-03-15 | -$82.18M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$5.97M 10-Q · filed 2022-11-09 | -$61.78M derived: sum of 2 quarters · filed 2022-11-09 | -$69.20M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$55.80M 10-Q · filed 2022-08-01 | -$63.22M 10-Q · filed 2022-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |